NASDAQ:OHRP OHR Pharmaceutical (OHRP) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free OHRP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.43▼$0.4550-Day Range$5.39▼$9.0752-Week Range$1.60▼$6.28Volume25,641 shsAverage Volume180,228 shsMarket Capitalization$1.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get OHR Pharmaceutical alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About OHR Pharmaceutical Stock (NASDAQ:OHRP)OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.Read More Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. OHRP Stock News HeadlinesApril 14, 2024 | benzinga.comPharmaceutical StocksMarch 17, 2024 | seekingalpha.comCYCC Cyclacel Pharmaceuticals, Inc.April 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.September 12, 2021 | ca.finance.yahoo.comOHR Pharmaceutical (OHRP) is now in Oversold TerritorySee More Headlines Receive OHRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OHR Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2018Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OHRP CUSIPN/A CIK1173281 Webwww.ohrpharmaceutical.com Phone212-682-8452FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,230,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-75.46% Return on Assets-71.18% Debt Debt-to-Equity RatioN/A Current Ratio3.73 Quick Ratio3.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.86 per share Price / Book0.11Miscellaneous Outstanding Shares2,829,000Free FloatN/AMarket Cap$1.25 million OptionableNot Optionable Beta0.84 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Jason Scott Slakter (Age 61)CEO, Pres & Director Mr. Samuel Backenroth (Age 35)CFO, VP of Bus. Devel. & Sec. Dr. Glenn L. Stoller M.D. (Age 55)Chief Scientific Officer Dr. Marlene ModiHead of Preclinical & Regulatory AffairsKey CompetitorsSunshine BiopharmaNASDAQ:SBFMComera Life SciencesNASDAQ:CMRABiodexa PharmaceuticalsNASDAQ:BDRXGRI BioNASDAQ:GRIPanbela TherapeuticsNASDAQ:PBLAView All Competitors OHRP Stock Analysis - Frequently Asked Questions How were OHR Pharmaceutical's earnings last quarter? OHR Pharmaceutical Inc (NASDAQ:OHRP) announced its quarterly earnings data on Tuesday, August, 14th. The biotechnology company reported ($0.20) earnings per share for the quarter. When did OHR Pharmaceutical's stock split? Shares of OHR Pharmaceutical reverse split on Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 1st 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of OHR Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other OHR Pharmaceutical investors own include Actinium Pharmaceuticals (ATNM), TherapeuticsMD (TXMD), Cytori Therapeutics (CYTX), Synergy Pharmaceuticals (SGYP), IVERIC bio (OPHT), Novavax (NVAX), Immunomedics (IMMU), OPKO Health (OPK), Dynavax Technologies (DVAX) and Energy Transfer (ET). This page (NASDAQ:OHRP) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OHR Pharmaceutical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
